No Data
No Data
Goldman Sachs Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Cuts Target Price to $26
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $80
Buy Rating for Arrowhead Pharmaceuticals Driven by Promising ARO-C3 Trial Results and Strategic Pipeline Advancements
Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients
Express News | Arrowhead Pharmaceuticals Inc - No Serious or Severe Treatment Emergent Adverse Events Reported